Fox Run Management, L.L.C. Amylyx Pharmaceuticals, Inc. Transaction History

Fox Run Management, L.L.C.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$12.07 - $18.46 $60,615 - $92,706	5,022 Added 29.57%	22,007 $323,000
Q3 2023 Nov 07, 2023	SELL	$18.08 - $23.45 $18,206 - $23,614	-1,007 Reduced 5.6%	16,985 $310,000
Q2 2023 Aug 11, 2023	BUY	$20.98 - $31.42 $115,264 - $172,621	5,494 Added 43.96%	17,992 $388,000
Q1 2023 May 12, 2023	BUY	$27.71 - $40.93 $346,319 - $511,543	12,498 New	12,498 $366,000

127

44.4M

235K

530K

Ticker AMLX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,533,200
Market Cap $310M
Description
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...

Get notified when there are updates to the investment portfolio of Fox Run Management, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Fox Run Management, L.L.C. with notifications on news.